Send to

Choose Destination
Invest New Drugs. 1994;12(2):143-5.

Phase II trial of topotecan in patients with advanced renal cell carcinoma.

Author information

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.


Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan. None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity. Eighty percent (12 of 15) of patients experienced grade III or IV neutropenia and/or anemia. Topotecan is not efficacious in the treatment of advanced renal cell carcinoma.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center